Search
Results
showing 1-10 of 5661
The Impact Report
The Impact Report highlights the power of advocacy, research translation, and partnership to advance HIV prevention and global health equity. In this first edition — the introduction of LEN in Zambia, how AVAC and partners are standing up for science, and new efforts to translate evidence for decision making.
Bridging the Gap Between Science and Communities
In a moment when access to clear, credible HIV science has never been more urgent, AVAC is bridging the gap between global research conferences and the communities who need that information most—through real-time webinars, digestible recaps, and resources trusted by leading researchers.
Standing Up for Science
As the US administration threatens to dismantle decades of biomedical research progress, AVAC and partners have mounted a powerful defense—highlighted by the 24-Hour Marathon to Save AIDS Research, which united 75 presenters and reached more than 7,000 people across 28 countries.
Strengthening Access Planning
Zambia made history on World AIDS Day 2025 by becoming one of the first African countries to launch lenacapavir—just 18 months after pivotal trial results were announced. This milestone reflects years of coordinated advocacy, community engagement, and technical support that’s setting a new standard for speed and equity in HIV prevention rollouts globally.
AVAC Roundup: Must-See Resources from the Last Week
From spotlighting the impact of US-supported HIV research to advancing the future of the HIV response; accelerating pediatric HIV cure research to shaping the global STI agenda, AVAC is driving and tracking the critical conversations defining HIV prevention and advocacy. Read on for this week’s resources and perspectives.
Opportunities, Controversies & Cruel Ironies
View the slides from AVAC Executive Director Mitchell Warren plenary presentation at SYNChronicity 2026.
Global Health Watch: Court Blocks ACIP Overhaul, NIH Director Promises to Disburse Funds, State Dept Pulls “America First” Health MoUs
A US federal court blocked the US Administration’s efforts to overhaul the CDC’s Advisory Committee on Immunization Practices, while the NIH Director sought to reassure lawmakers over funding delays and shifting research priorities. Meanwhile, the State Department quietly removed five “America First” health agreements from public access as scrutiny grows, and Argentina announced its intent to withdraw from the WHO.
The Power of bNAbs: A new frontier in HIV cure research
In this video, from the Series of Jojo, viewers are introduced to broadly neutralizing antibodies (bNAbs) and how they might one day be used in finding a functional cure for HIV.
EXPrESSIVE Phase III Program Countries of MK-8527
Seventeen countries are hosting sites for the Phase 3 efficacy trials of a monthly PrEP pill, MK-8527, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase 3 trials at IAS 2025 in Kigali. MK-8527 was found to be safe and well-tolerated in Phase 2 clinical trials.
showing 1-10 of 5661